NCT01938482View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 17, 2015

Study Completion Date

February 17, 2015

Conditions
Acne Vulgaris
Interventions
DRUG

0.3% GSK1940029 gel

Will be supplied as gel for topical application

DRUG

1% GSK1940029 gel

Will be supplied as gel for topical application

DRUG

0.3%/1% vehicle gel only

Will be supplied as gel for topical application

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01938482 - Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029 | Biotech Hunter | Biotech Hunter